about
POT1 loss-of-function variants predispose to familial melanomaAsthma is associated with multiple alterations in anti-viral innate signalling pathwaysGenetics of familial melanoma: 20 years after CDKN2A.Adaptive immunity to rhinoviruses: sex and age matter.Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanomaHigh efficiency ex vivo cloning of antigen-specific human effector T cellsA polymorphic variation in the interleukin 1A gene increases brain microglial cell activity in Alzheimer's diseasePOLE mutations in families predisposed to cutaneous melanoma.Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotypeRole of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease.Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients.Recurrent inactivating RASA2 mutations in melanoma.Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary diseaseMolecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.The plasmacytoid dendritic cell: at the cross-roads in asthma.Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.Exploration of peptides bound to MHC class I molecules in melanoma.BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib.Whole-genome landscapes of major melanoma subtypes.Exome Sequencing to Predict Neoantigens in Melanoma.A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma.Are rhinoviral proteinases responsible for mixed T(H)1 and T(H)2 immunity in chronic obstructive pulmonary disease?Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma.Innate IFNs and plasmacytoid dendritic cells constrain Th2 cytokine responses to rhinovirus: a regulatory mechanism with relevance to asthma.Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease.Intergenic disease-associated regions are abundant in novel transcripts.A polymorphism in the angiotensin 1-converting enzyme gene is associated with damage to cerebral cortical white matter in Alzheimer's disease.Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease.Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer's disease.A 3'-UTR polymorphism in the oxidized LDL receptor 1 gene increases Abeta40 load as cerebral amyloid angiopathy in Alzheimer's disease.Mutation load in melanoma is affected by MC1R genotype.Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease.Innate interferons inhibit allergen and microbial specific T(H)2 responses.Targeting Neoantigens for Personalised Immunotherapy.No association between neuregulin 1 and psychotic symptoms in Alzheimer's disease patients.Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.A SNP in the ACT gene associated with astrocytosis and rapid cognitive decline in AD.A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combinationBone marrow transplantation generates T cell-dependent control of myeloma in miceIdentifying neoantigens for use in immunotherapy
P50
Q24563091-916E0365-D67D-494A-9348-0ED229AE9788Q34155757-102B2F31-3B84-4219-93B1-575099959FA6Q34449957-A7D9AAA6-A1D2-4449-B8A3-6945A52D1DB2Q34506590-0988BD66-0A67-4FC7-ACA8-5C56AB972D71Q35102528-39FCC73B-C147-4A74-A5D0-26CD3BBAC481Q35391415-3EE5C306-BA0F-423B-B7BB-A6AB6844054CQ35477437-529AEF70-D5F3-4CF2-BB0D-DC3FA4B27AF0Q35739446-582F89D3-8E73-49CF-850D-074D7ECA4CCDQ36142328-27390DE0-9469-4217-A581-2190F9589FA4Q36650698-66BBDBF8-E44F-4F35-AD47-2CAC9F0ADAE3Q36906620-C9BF0966-87FB-46E1-B750-AE2425D141E7Q37112088-CD99B3DA-AF28-49F5-9121-8253C48BFA03Q37419373-071B68EF-86CD-41BC-A0E8-0F07ADE2342FQ38081268-CEC3F6E3-7F63-4CF8-A7DD-C571BA809203Q38083545-93A3D996-9042-4573-8CA8-99D34515E440Q38613449-01987AA0-9B57-46D7-98C4-B6E291C7DE01Q38913724-E641F67B-A23F-4E7B-8644-2814BE153620Q38954343-F7E1B091-D653-403F-82D2-3C021F4BC7ECQ39060449-9B712DA0-9A8E-4B50-A19D-3E39F11A140DQ40864095-1689E972-9A5A-4521-A977-36361BD8EDDEQ42465699-47D5FD2A-E383-4244-87BD-19B8EAC1A3E7Q42936192-47945F98-906D-4B14-B50D-B15565E8ADD8Q43274590-3F362906-9A48-48C1-8D96-02738E80B329Q44563219-37C85E13-8017-40EA-9362-B704A2433254Q44802731-62CCBA48-99A5-4F4B-BAB1-67D3BBFEF3A9Q47101089-38E38BD6-F1FE-4B9E-A22B-E64DEFD02B78Q47293922-EEA03A41-B32A-4B99-83EC-62C14783A340Q47354992-C0C56CCE-429F-4E10-A0FC-FF959EC86011Q47586154-566920AA-0174-41A0-B501-CE71E071CDA5Q47606048-DE8C477F-4DD7-4343-AAF1-038C1EA25311Q48117792-658E3338-3A1D-40C7-83C7-11303025C5C8Q48878851-04F1AF79-E9DB-4637-BAD1-5ABEE65DC276Q50945825-8B282681-C97D-4A2E-8B45-9020B624372CQ52363330-4796EC19-F4D7-46A5-B7AC-CF6DB15650CEQ53308047-B75708FC-7A14-420C-AC02-3AA76C19E154Q54116561-D169B9F2-EDE4-482A-830E-5FD28B3AA05CQ55043630-6894788F-9468-4212-8F79-795B5A9AA5FDQ57008980-0C7662F4-01FA-494C-90A3-6B69DE5519C8Q57289945-FEFA0112-5347-4D81-90A0-BB5BF0EE953EQ62050532-C20FE0B7-D388-4241-A280-67CFAEBB1BFC
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonia Pritchard
@ast
Antonia Pritchard
@en
Antonia Pritchard
@es
Antonia Pritchard
@nl
type
label
Antonia Pritchard
@ast
Antonia Pritchard
@en
Antonia Pritchard
@es
Antonia Pritchard
@nl
prefLabel
Antonia Pritchard
@ast
Antonia Pritchard
@en
Antonia Pritchard
@es
Antonia Pritchard
@nl
P108
P1053
F-4288-2010
P106
P108
P21
P31
P3829
P496
0000-0001-5336-0454